The Use of Critical Process Parameters and Quality By Design to Improve Biopharmaceutical Product Quality
|
|
- Chrystal Gray
- 7 years ago
- Views:
Transcription
1 The Use of Critical Process Parameters and Quality By Design to Improve Biopharmaceutical Product Quality Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc.
2 Presented at BioProcess International Asia Pacific Mumbai, India October 21, 2008 and 2008 PDA Development and Regulation of Clinical Trial Supplies Conference Cambridge, MA November 11, 2008
3 What is Quality by Design? Means that product and process performance characteristics are scientifically designed to meet specific objectives, not merely empirically derived from performance of test batches. The product is designed to meet patient needs and performance requirements The process is designed to consistently meet product critical quality attributes The impact of starting raw materials and process parameters on product quality is well understood The process is continually monitored, evaluated and updated to allow for consistent quality throughout product life cycle Critical sources of variability are identified and controlled through appropriate control strategies Ref: H. Winkle, BPI Conference, Oct 1 4, 2007
4 Defining Critical Quality Attributes (CQAs) those molecular and biological characteristics found to be useful in ensuring the safety and efficacy of the product (Q6B) Can these attributes be properly defined for biologics? Often difficult due to complexity of biologic products Default is to look at many attributes QbD focuses only on critical product attributes and the impact of those attributes across their ranges on safety and efficacy Product specifications based on mechanistic understanding of how formulation and process factors impact product performance Need to develop a design space to be documented in application which is based on CQAs
5 What are Critical Process Parameters (CPPs) CPPs are independent process parameters most likely to affect the quality attributes of a product or intermediate CPPS are determined by sound scientific judgment and based on research, scale up or manufacturing experience CPPS are controlled and monitored to confirm that the impurity profile is comparable to or better than historical data from development and manufacturing Quality attributes derived from CPPs include: Chemical purity Qualitative and quantitative impurities Physical characteristics Microbial quality
6 QbD for Small Molecules vs. Biologics Small Molecule Drugs Variability derived from formulated Drug Product Quality Attributes determined early in product development Readily Characterized Process control readily defined and achieved Biologic Products Variability derived from Drug Substance Quality Attributes difficult to determine; defined late in product development Characterization Complex Process control more difficult to define and implement
7 The Application of QbD to Biologic Products Quality by Design is an important element in achieving desired state, however, we re not there yet Determining relationship between Quality specifications and safety or efficacy results Clinical Activity and Critical Quality Attributes Product Attributes and Critical Process Parameters Process Validation and the Design Space Insufficient Data on Key versus Critical Strong Conservatism on both sides Traditional development and validation approaches can be applied to QbD, especially in identifying CPP and defining the Design Space
8 Knowledge Space Ref: B. Davis, FIP Conference 2007
9 Defining CQAs Throughout a Product Life Cycle Critical aspects throughout product life cycle define what is needed: To release product To control the process For post approval changes Preclinical Phase 1 Phase 2 Phase 3 Post Approval Estimates Based on Experience Refined Based on Preclinical and Safety Data Refined Based on Clinical and Process Data Continually Reviewed and Refined Based on Increased Clinical
10 Linking Design Space and Control Strategies Design space is based on our Knowledge Space Control Strategy: Maintaining the process within the Design Space Design Space is not intended to define critical attributes, rather these will follow from the process flow The control strategy for a CQA is the selection and combination of different types of controls applied to the manufacturing process and associated systems to assure the right product quality at an acceptably low level of risk of manufacturing failure
11 Defining Control Strategies
12 CPP Drive CQA to Create the Design Space Range of Raw Material And Facility Attributes Process Designed to Limit Product Variability Define API in terms of CQAs Identify CPP that affect the CQAs Determine range of each CPP that produces acceptable product to establish the Design Space
13 Comparing CQAs and CPPs Process validation should provide documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes (ICH Q7A) Critical Quality Attributes derive from Critical Process Parameters Graphic adapted from Kozlowski and Swan (2006)
14 Design Space: Identification of CPPs Glycoform Flow Rate Yield ph Impurity 1 Column Loading Capacity Using data from development identify parameters that affect the defined product characteristics, for example Level of key impurity Desired glycoform content Desired yield
15 Design Space: Process Optimization Flow Rate ph Flow Rate ph Column Loading Capacity Column Loading Capacity Use Factorial Analysis without interactions to map boundary conditions Use Full Factorial to fully define response surfaces and examine interactions
16 Design Space: Putting it All Together Summarize results of multiple experiments to define response surface Glycoform Agitation Rate Yield [Fe] in Media Final OD Validate the process within the Design Space to demonstrate consistent production of product with desired characteristics Impurity 1 Design Space
17 Application of QbD to Cell Culture Optimizing clone selection to achieve maximal product titer within a Design Space Potential Critical Process Parameters in cell culture production Temperature ph Agitation Dissolved oxygen Medium constituents Feed type and rate
18 Optimization of Cell Culture Many potential process parameters can impact the Critical Quality Attributes of the cell culture process, including: Cell viability and number Product titer Product Characteristics (e.g. glycosylation) Impurity profile Identify those which are critical through process development evaluating impact of each parameter on the CQA Create Design Space by optimization of these parameters through a two factorial design of experiment
19 Optimization of Cell Culture Conditions Two factorial design monitoring product titer (yield) as a function of ph and temperature 50 conditions (10 T x 5 ph) n=9 (450 total chambers) Optimization performed using SimCell TM technology from BioProcessors Corp.
20 Mapping Downstream Process Design Space Critical Process Parameters in column chromatography Column bed height and packing efficiency Media selectivity Dynamic capacity for product and total protein Buffer conditions (ph, conductivity) Temperature Flow rate ranges Sample load ranges Media particle size and size range All impact product purity and yield
21 Defining Ion Exchange Column Conditions Purification of a natural protein by anion exchange chromatography Anion exchange column equilibrated with 10 mm TRIS Phosphate buffer Variation of load solution ph will impact product yield and purity
22 Anion Exchange Column Yield and Purity Best yield at ph 7.0, however, additional contaminant present in pool not seen at higher ph s Product Contaminant Can subsequent process steps remove this contaminant?
23 Final Product Purity Subsequent purification of Anion Exchange Column pool removes process contaminant regardless of ph at which Anion Exchange column is run A Anion exchange column pool, ph 7.0 B Anion exchange column pool, ph 8.6 C Column 2 pool following loading with A D Column 2 pool following loading with B
24 Summary and Conclusions Application of QbD to biopharmaceutical products is often difficult reflecting the complexity of these products Process development of biologics has always included some aspects of QbD, including science based decisions and the use of scale down process models Once optimized, CPP ranges can be used to define the design space for biologic manufacturing processes
25 Summary and Conclusions Combining DOE with science based decisions can decrease the time required to optimize production, speed the development of robust processes, and reduce risk in biologics product development Using QbD can facilitate the technology transfer by describing the design space for complex products and allowing process variability
26 Acknowledgements BioProcess Technology Consultants Sheila Magil, Ph.D. Susan Dana Jones, Ph.D. Alex Kanarek, Ph.D. BioProcessors, Inc. Cell culture optimization Neurobiological Technologies, Inc. Chromatography optimization
27 THANK YOU! For more information, contact Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. 289 Great Road, Suite 303 Acton, MA (fax)
Process Validation: Practical Aspects of the New FDA Guidance
Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationWhat to control? CQAs and CPPs
What to control? CQAs and CPPs Dr. Thomas Stangler On behalf of the European Generic medicines Association Development Strategy & Technology Manager Sandoz Biopharmaceuticals 1 Martin Schiestl Singapore,
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationWorkshop B Control Strategy
ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation
More informationQbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins
QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins 2015. 06. 09 Green Cross Corp. Green Cross Research Center Yong Jae Kim (YJKIM@greencross.com) Biologics World
More informationWorkshop on process validation
Workshop on process validation CMC Strategy Forum Europe 2013 EBE Process validation satellite session Pragues, 06/05/2013 Kowid Ho Scope / background Process evaluation/validation of biotechnology derived
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationAccelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches
Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches 2008 IBC Formulation Strategies for Protein Therapeutics Tim Kelly, Ph.D.
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationWorkshop A Design Space (DS)
Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information
More informationPHARMACEUTICAL DEVELOPMENT
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL DEVELOPMENT Q8(R2) Current Step
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
More informationQuality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011
Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical
More informationQuality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party
Quality by Design Application and Perspectives for biologicals K. Ho, CHMP Biologics Working Party Pharmaceutical development (Q8) Aim: To design a quality product and a manufacturing process to consistently
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationProcess-scale purification of monoclonal antibodies polishing using Capto Q
GE Healthcare Life Sciences Application note 28-937-16 AB Ion exchange chromatography Process-scale purification of monoclonal antibodies polishing using Capto Q Summary Anionic exchange media are an industry
More informationWorkshop on process validation
Workshop on process validation General concepts on process validation Kowid Ho Scope / background Process evaluation/validation of biotechnology derived proteins used as active substance in the manufacture
More informationInternational GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationICH guideline Q8, Q9 and Q10 - questions and answers volume 4
December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December
More informationICH Topic Q 5 E Comparability of Biotechnological/Biological Products
European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES
More informationConsiderations in Setting Specifications
EBE Concept Paper Considerations in Setting Specifications March 28, 2013 European Biopharmaceutical Enterprises (EBE), a specialised group of EFPIA Leopold Plaza Building Rue du Trône 108 BE-1050 Brussels
More informationDesign of Experiments for Analytical Method Development and Validation
Design of Experiments for Analytical Method Development and Validation Thomas A. Little Ph.D. 2/12/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationBest Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
More informationHow To Develop A Cell Line
Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen
More informationImplementing New USP Chapters for Analytical Method Validation
Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationTHE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS Table of Contents CHAPTER 1: Overview of Monoclonal Antibody Therapeutics CHAPTER 2: Monoclonal Antibody Discovery Technologies CHAPTER 3: CMC
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationRisk analysis and management is the cornerstone
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE This article presents a new type of risk tool. Risk Analysis and Mitigation Matrix (RAMM) was developed to be incorporated into a
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationGuidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationHiPer Ion Exchange Chromatography Teaching Kit
HiPer Ion Exchange Chromatography Teaching Kit Product Code: HTC001 Number of experiments that can be performed: 5 Duration of Experiment: Protocol: 5-6 hours Storage Instructions: The kit is stable for
More informationUse of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development
Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationGuide to Reverse Phase SpinColumns Chromatography for Sample Prep
Guide to Reverse Phase SpinColumns Chromatography for Sample Prep www.harvardapparatus.com Contents Introduction...2-3 Modes of Separation...4-6 Spin Column Efficiency...7-8 Fast Protein Analysis...9 Specifications...10
More informationpencil. Vocabulary: 1. Reactant 2. Product 3. Activation energy 4. Catalyst 5. substrate 6. Chemical reaction Keep your textbooks when you are done
Objectives Students will explore the importance of chemical reactions in biology Students will discuss the role of enzymes as catalysts in biological reactions. Students will analyze graphs showing how
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q6B. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
More informationGUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
More informationANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS
VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external
More informationQbD Approach to Assay Development and Method Validation
QbD Approach to Assay Development and Method Validation Thomas A. Little Ph.D. 11/105/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationQ8(R2): Pharmaceutical Development
ICH-GCG ASEAN Q8(R2): Pharmaceutical Development Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference
More informationData Mining Builds Process Understanding for Vaccine Manufacturing
Data Mining Builds Process Understanding for Vaccine Manufacturing WCBP 2009 Current Topics in Vaccine Development January 14, 2009 Julia O Neill, Principal Engineer Merck & Co., Inc. Global Vaccine Technology
More informationGain efficiency in your process development with ÄKTA avant
Gain efficiency in your process development with ÄKTA avant gelifesciences.com Gain efficiency in your process development with ÄKTA avant Development of efficient manufacturing processes is a necessity
More informationIt is generally accepted that quality
B i op r o c e s s Technical Practical Considerations for DoE Implementation in Quality By Design Mahesh Shivhare and Graham McCreath It is generally accepted that quality cannot be tested or inspected
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationApplication Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary
Application Note Increasing the activity of monoclonal antibody isoforms by MCSGP Category Matrix Method Keywords Countercurrent chromatography, FPLC Antibodies MCSGP FPLC, Biobetters, MCSGP, countercurrent
More informationPRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY
PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY Guideline Title Production and Quality Control of Medicinal Products derived by recombinant DNA Technology Legislative
More informationQbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance
QbD Understanding How Excipient Properties Influence Solid Oral Dosage Form Performance Dr Amina Faham (Dow), Dr Liz Meehan (AstraZeneca) ExcipientFest, Amsterdam NL June 24, 2014 What do you understand
More informationSingle Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography
www.natrixseparations.com Complex Separations Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography AN1000 Summary Recombinant Shiga toxin
More informationApplication Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary
Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,
More informationMethod Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates
Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Paula Hong and Kenneth J. Fountain Waters Corporation, 34 Maple St., Milford, MA, USA APPLICATION
More informationCleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
More informationControl Strategy Case Studies
Control Strategy Case Studies Vance Novack, GSK Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing, China, Dec 2008 Control Strategy Case Studies The information and knowledge
More informationA Risk Assessment of Pre-Licensure Manufacturing Changes
A Risk Assessment of Pre-Licensure Manufacturing Changes Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical Science FDA-CDER
More informationGeneral Properties Protein Nature of Enzymes Folded Shape of Enzymes H-bonds complementary
Proteins that function as biological catalysts are called enzymes. Enzymes speed up specific metabolic reactions. Low contamination, low temperature and fast metabolism are only possible with enzymes.
More informationAssay Development and Method Validation Essentials
Assay Development and Method Validation Essentials Thomas A. Little Ph.D. 10/13/2012 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationGUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 19 to 23 October 2009 GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) World Health Organization 2009 All rights
More informationPharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics
Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics Lawrence X. Yu, Ph.D. Deputy Director Office of Pharmaceutical Quality Center for Drug Evaluation and Research Food and Drug
More informationQuality by Design (QbD) Overview
Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System
More informationQUALITY BY DESIGN (QBD) : A COMPLETE REVIEW
Review Article QUALITY BY DESIGN (QBD) : A COMPLETE REVIEW Nishendu P. Nadpara*, Rakshit V. Thumar, Vidhi N. Kalola, Parula B. Patel Department of Quality Assurance, S. J. Thakkar Pharmacy College, Opp.
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationMarmara Üniversitesi Fen-Edebiyat Fakültesi Kimya Bölümü / Biyokimya Anabilim Dalı PURIFICATION AND CHARACTERIZATION OF PROTEINS
EXPERIMENT VI PURIFICATION AND CHARACTERIZATION OF PROTEINS I- Protein isolation and dialysis In order to investigate its structure and properties a protein must be obtained in pure form. Since proteins
More informationA novel AIEX chromatography medium (resin) to remove IgA and IVIG purification process
A novel AIEX chromatography medium (resin) to remove IgA and IVIG purification Guodong Javier Jia 1, Chor Sing Tan 2, Linus Laurin 3, Henrik Ihre 3, Lili Sui 1 1 Fast Trak China, GE Healthcare Life Sciences,
More informationAspects of industrial purification of peptides using large-scale chromatography. Lars Andersson and Jonas Persson
Aspects of industrial purification of peptides using large-scale chromatography Introduction By Lars Andersson and Jonas Persson PolyPeptide Laboratories (Sweden) AB PO Box 30089 SE-200 61 LIMHAMN SWEDEN
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationPeptide purification strategies
Särö Conference 2009 Peptide purification strategies Ulf Altenhöner Lonza Exclusive Synthesis R&D Outline Introduction Integrated process development Model-based process development Inspiration Conclusions
More informationHOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER
HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE
More informationDrive Process Productivity
Solutions for the Biopharmaceutical Industry Drive Process Productivity Innovative solutions from a proven technology leader Your partner in productivity Whether you are developing a process for a novel
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationSIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN TABLET DOSAGE FORM USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
CHAPTER 5 SIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN TABLET DOSAGE FORM USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 5 Simultaneous determination of Telmisartan
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Step 5
European Medicines Agency September 1999 CPMP/ICH/365/96 ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON SPECIFICATIONS:
More informationLifeTein in Industrial Production of Therapeutic Peptides. Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA
LifeTein in Industrial Production of Therapeutic Peptides Phil Moore, PhD Director of Business Development LifeTein LLC, NJ, USA 1 Outline Market and Technology Trend LifeTein s Technology portfolio LifeTein
More informationBringing Downstream Productivity into Phase with Upstream Antibody Production
Bringing Downstream Productivity into Phase with Upstream Antibody Production Pete Gagnon, Validated Biosystems 3 rd International Monolith Symposium, Portoroz, May 30 June 4, 2008 The need for speed When
More informationCleaning and Contamination Control
Cleaning and Contamination Control A regulatory perspective Lynn Talomsin Senior Inspector, Manufacturing Quality Branch, TGA Control Practices Cleaning and Contamination Control Contamination control
More informationChemistry at Work. How Chemistry is used in the Water Service
Chemistry at Work How Chemistry is used in the Water Service WATER TREATMENT Everyday, more than 100 water treatment works in Northern Ireland put approximately 680 million litres of water into the supply
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationData File. Sephadex G-25 media and pre-packed columns. Introduction. Sephadex G-25 Bead structure. Desalting/buffer exchange and gel filtration
P H A R M A C I A B I O T E C H Sephadex G-25 media and pre-packed columns Data File Desalting/buffer exchange and gel filtration Reproducible desalting and buffer exchange in minutes with 90% 100% recovery
More informationAnnex 6. Guidance on variations to a prequalified product dossier. Preface
Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi
More information